Celine De Schrijver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celine De Schrijver has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alisha Atmopawiro
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 1
11 shared publications - Carmela Dell’aVersana
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
11 shared publications - Cemile Dilara Savci-Heijink
Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
11 shared publications - Crescenzo Massaro
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 1
11 shared publications - Cristina Giorgio
Research & Early Development (R&D) Dompé Farmaceutici SpA Naples Italy
11 shared publications - Cristina Gómez-Martín
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
11 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 9. a) BLI images of tumor-bearing mice receiving Ladarixin and injected or not with human EV-induced iMSCs. b-c) Tumor growth measured by caliper (b) and lung nodules count (c) in tumor-bearing mice receiving ladarixin in combination with EW-7197 (TGFBR1 inhibitor) and injected or not with human EV-induced iMSCs.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 9. a) BLI images of tumor-bearing mice receiving Ladarixin and injected or not with human EV-induced iMSCs. b-c) Tumor growth measured by caliper (b) and lung nodules count (c) in tumor-bearing mice receiving ladarixin in combination with EW-7197 (TGFBR1 inhibitor) and injected or not with human EV-induced iMSCs.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 8. a-c) RNA class distribution of osteosarcoma (n=10) (a) and multiple myeloma (n=5) (b) patient plasma EVs, and normalized counts (rpm) of known (TLR-3 and RIG-I activating) inflammatory RNAs in osteosarcoma plasma EVs, MM plasma EVs and 143B EVs (c). d) Expression levels of (endosomal and cytosolic) pattern recognition receptors in MSCs based on normalized RNA-seq counts. e-h) Knockdown confirmation of TLR3 (e), RIG-I (f), MDA5 (g) and LGP2 (h) in primary MSCs as compared to control (shGFP-transduced) cells. i) IL8 protein production in MSCs transduced with indicated shRNAs upon exposure to 143B EVs. Graph shows data from a replicate experiment performed using MSCs from donor #2.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 8. a-c) RNA class distribution of osteosarcoma (n=10) (a) and multiple myeloma (n=5) (b) patient plasma EVs, and normalized counts (rpm) of known (TLR-3 and RIG-I activating) inflammatory RNAs in osteosarcoma plasma EVs, MM plasma EVs and 143B EVs (c). d) Expression levels of (endosomal and cytosolic) pattern recognition receptors in MSCs based on normalized RNA-seq counts. e-h) Knockdown confirmation of TLR3 (e), RIG-I (f), MDA5 (g) and LGP2 (h) in primary MSCs as compared to control (shGFP-transduced) cells. i) IL8 protein production in MSCs transduced with indicated shRNAs upon exposure to 143B EVs. Graph shows data from a replicate experiment performed using MSCs from donor #2.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 4. a-b) scRNA-seq mapping of human osteosarcoma tumors. MSC and other indicated clusters were identified through the UMAP (a) and marker gene expression analysis (b).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 4. a-b) scRNA-seq mapping of human osteosarcoma tumors. MSC and other indicated clusters were identified through the UMAP (a) and marker gene expression analysis (b).
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 2. a-b) scRNA-seq mapping of the non-hematopoietic mononuclear cell fraction from bone marrow aspirates of MM patients and non-cancer control individuals. UMAP plot (a) and violin plots (b) of marker gene expression in the identified clusters. c) UMAP plot split into control and MM datasets. d-i) Density plots of differentially expressed cytokines and chemokine in control and MM samples.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 2. a-b) scRNA-seq mapping of the non-hematopoietic mononuclear cell fraction from bone marrow aspirates of MM patients and non-cancer control individuals. UMAP plot (a) and violin plots (b) of marker gene expression in the identified clusters. c) UMAP plot split into control and MM datasets. d-i) Density plots of differentially expressed cytokines and chemokine in control and MM samples.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 1. a-b) Tumor growth measured by caliper (a) and BLI (b) in osteosarcoma-bearing mice receiving the TGFBR1 inhibitor EW-7197 and injected or not with 143B EV-educated MSCs. c) Western blot for CD63 and CD81 in EVs released by human fibroblasts (hF) and 143B, MDA-MB-231, PC3, HOS and MCF7 cell lines. d) GSEA enrichment plot for gene set ‘TNFα signaling via NFKB’ in 143B EV-exposed MSC compared to hF EV-exposed (ctrl) MSCs. e) List of gene sets enriched in 143B EV-exposed MSCs compared to hF EV-exposed (ctrl) MSCs.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 1. a-b) Tumor growth measured by caliper (a) and BLI (b) in osteosarcoma-bearing mice receiving the TGFBR1 inhibitor EW-7197 and injected or not with 143B EV-educated MSCs. c) Western blot for CD63 and CD81 in EVs released by human fibroblasts (hF) and 143B, MDA-MB-231, PC3, HOS and MCF7 cell lines. d) GSEA enrichment plot for gene set ‘TNFα signaling via NFKB’ in 143B EV-exposed MSC compared to hF EV-exposed (ctrl) MSCs. e) List of gene sets enriched in 143B EV-exposed MSCs compared to hF EV-exposed (ctrl) MSCs.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 7. a) Dynasore-mediated inhibition of PKH67-labeled EV uptake by MSCs as assessed by FACS. b-e) Relative expression levels of CXCL2, CXCL5, CXCL3, CXCL6 in MSCs treated with 143B EVs in the presence or absence of dynasore. Transcript levels are normalized to GAPDH and expressed as fold increase relative to the experimental controls (untreated or dynasore-treated MSCs). Graphs show the average of 3 (CXCL2 and CXCL6) or 2 (CXCL3 and CXCL5) experiments. Statistics was calculated on normalized expression data, *p < 0.05, two-tailed t test. f) Volcano plots depicting differentially expressed interferon stimulated genes (ISGs) in MSCs exposed to 143B EVs, and relative log2FC and FDR values. Human fibroblast (hF) EVs were used as control vesicles. g-j) Expression of the ISGs IFIT1, IFITM1, MX1 and OAS2 in BM-MSCs upon transfection with (143B) EV RNA pre-treated or not with RNase III or RNase A. k-n) Syntenin, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRNAs against syntenin or GFP as non-targeting control, in the presence or absence of doxycycline. o-r) RAB35, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRab35 or shGFP in the presence or absence of doxycycline.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 7. a) Dynasore-mediated inhibition of PKH67-labeled EV uptake by MSCs as assessed by FACS. b-e) Relative expression levels of CXCL2, CXCL5, CXCL3, CXCL6 in MSCs treated with 143B EVs in the presence or absence of dynasore. Transcript levels are normalized to GAPDH and expressed as fold increase relative to the experimental controls (untreated or dynasore-treated MSCs). Graphs show the average of 3 (CXCL2 and CXCL6) or 2 (CXCL3 and CXCL5) experiments. Statistics was calculated on normalized expression data, *p < 0.05, two-tailed t test. f) Volcano plots depicting differentially expressed interferon stimulated genes (ISGs) in MSCs exposed to 143B EVs, and relative log2FC and FDR values. Human fibroblast (hF) EVs were used as control vesicles. g-j) Expression of the ISGs IFIT1, IFITM1, MX1 and OAS2 in BM-MSCs upon transfection with (143B) EV RNA pre-treated or not with RNase III or RNase A. k-n) Syntenin, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRNAs against syntenin or GFP as non-targeting control, in the presence or absence of doxycycline. o-r) RAB35, IL8, CXCL2 and CXCL3 mRNA expression levels in 143B stably transduced with dox-inducible shRab35 or shGFP in the presence or absence of doxycycline.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 6. a-b) Expression of the most upregulated TGFβ-dependent (a) and independent/partially dependent (b) genes in bone marrow MSCs based on RNA-seq normalized counts. c-f) Relative expression levels of CXCL1, CXCL2, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #1) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor SB-431542 as assessed by RT-qPCR. g-m) Relative expression levels of IL6, IL8, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #2) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor EW-7197. n-o) Relative expression of IL6 and IL8 mRNAs in adipose-derived MSCs (donor #3) exposed to 143B EVs in the presence or absence of EW-7197.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 6. a-b) Expression of the most upregulated TGFβ-dependent (a) and independent/partially dependent (b) genes in bone marrow MSCs based on RNA-seq normalized counts. c-f) Relative expression levels of CXCL1, CXCL2, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #1) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor SB-431542 as assessed by RT-qPCR. g-m) Relative expression levels of IL6, IL8, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 mRNAs in bone marrow MSCs (donor #2) exposed to 143B EVs in the presence or absence of the TGFBR1 inhibitor EW-7197. n-o) Relative expression of IL6 and IL8 mRNAs in adipose-derived MSCs (donor #3) exposed to 143B EVs in the presence or absence of EW-7197.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 3. a-e) Relative expression levels of IL6, IL8, CXCL2, CXCL3 and CXCL6 in MSCs from an independent donor (MSC#2) exposed to plasma-derived EVs from healthy donor #1 (H#1) and MM patient #1 (MM#1).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 3. a-e) Relative expression levels of IL6, IL8, CXCL2, CXCL3 and CXCL6 in MSCs from an independent donor (MSC#2) exposed to plasma-derived EVs from healthy donor #1 (H#1) and MM patient #1 (MM#1).
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 5. a-b) CD63 (a) and CD81 (b) protein quantification (western blot pixel density) in EVs released by engineered (shGFP, shSyntenin, shRab11b, shRab35) 143B cells. c) Growth curve of wt and engineered (shGFP, shRab11b, shRab35, shSyntenin) 143B showing no differences in cell growth over 72 hours). d-e) Relative mRNA expression levels of IL6 (d) and IL8 (e) in MSCs exposed to indicated volumes of wild type 143B EVs.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development
Suppl. Figure 5. a-b) CD63 (a) and CD81 (b) protein quantification (western blot pixel density) in EVs released by engineered (shGFP, shSyntenin, shRab11b, shRab35) 143B cells. c) Growth curve of wt and engineered (shGFP, shRab11b, shRab35, shSyntenin) 143B showing no differences in cell growth over 72 hours). d-e) Relative mRNA expression levels of IL6 (d) and IL8 (e) in MSCs exposed to indicated volumes of wild type 143B EVs.